Preparation, Characterization and In Vitro Evaluation of Metformin Loaded Hyaluronic Acid Nanoparticles for Oral Delivery

Metformin, an anti-diabetic drug, has a low oral bioavailability (50-60%) due to its poor intestinal absorption. Orally administered mucoadhesive nanoparticles have been shown to interact with the intestinal mucus layer and increase the intestinal permeability of the entrapped drug. The objective of the present study was to develop and characterize polymeric nanoparticulate system containing metformin with a mucoadhesive polymer hyaluronic acid. Blank and drug loaded nanoparticles were prepared using hyaluronic acid polymer by precipitation method with a high entrapment efficiency. The average particle size of the blank and drug loaded nanoparticles was found to be 155.52 ±18.70 nm and 114.53 ± 12.01 nm, respectively. Atomic force microscopy (AFM) revealed that the nanostructures were in form of nanofibres. Zeta potential was found to be in the range of -0.27 to 0.24 mV. Physical stability studies indicated that the particle size was maintained at < 200 nm, and no change in zeta potential values over a period of 65 days. Differential Scanning Calorimetry and X-ray diffraction analysis indicated that the drug was present in a crystalline state in the matrix. The in vitro drug release studies showed that >50% of metformin was released within one hour. Metformin nanoparticles were non-toxic at a concentration of ≤ 100 µM in Cacco-2 cells. Haemolysis studies indicated that these nanoparticles can also be safely administered via intravenous route. Cellular uptake studies on Caco-2 cells indicated higher uptake of metformin from nanoparticle relative to that from metformin solution, up to first 45 minutes. Permeability studies indicated no passive permeation of the nanoparticles through a synthetic membrane lacking mucin. Thus requires further in vivo studies in the future with more bio-relevant environment like Caco-2 cells or porcine intestine. Diabetes is a disease affecting millions of people globally. The outcomes of this study could increase bioavailability, reduce dose and side effects of the metformin (widely used first line therapy for type 2 diabetes) which could impact humanity globally.

Grantor dc:publisher

Creighton University

Year dc:date.issued

2016

Author dc:creator

• Bhujbal, Sonal

Advisor dc:contributor.advisor

• Dash, Alekha K.

Statement dc:rights

• Copyright is retained by the Author. A non-exclusive distribution right is granted to Creighton University and to ProQuest following the publishing model selected above.

Language dc:language.iso

en_US

Handle dc:identifier.uri

http://hdl.handle.net/10504/90244

OAI identifier oai:identifier

oai:cdr.creighton.edu:10504/90244